Drugs / Pindolol
Pindolol
also known as
(+/-)-LB-46 · (rs)-pindolol · Apo-pindol · Betadren · Betapindol · Blocklin-l · Calvisken · Carvisken · +13 more
Small molecule targets ADRB1, ADRB2 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VISKEN | — | 1983-06-02 | fda.gov ↗ |
| Approved | US (FDA) | VISKEN | — | 1982-09-03 | fda.gov ↗ |
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07565493 | Aug 2026 → Jun 2028 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06028321 | Nov 2021 → Jun 2022 | hypoproteinemia, hypercatabolic | Actimed Therapeutics Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00895804 | Jun 2001 → Mar 2002 | mood disorder, substance-related disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01950520 | Feb 2014 → Dec 2022 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00931775 | Dec 2002 → Mar 2005 | major depressive disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01219686 | Oct 2010 → Apr 2013 | major depressive disorder | Markus KOSEL | Terminated | No outcome recorded Stop: Enrollment |
| Phase 43 trials | ||||||
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT00221494 | Jan 2004 → Jun 2006 | depressive disorder | Mark Frye | Withdrawn | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01778686 | Jan → Nov 2013 | — | Gitte Moos Knudsen | Completed | No outcome recorded |
| — | NCT00424801 | Jan 2007 → Dec 2008 | coronary microvascular disorder, essential hypertension | University of Aarhus | Terminated | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT01400165 Comparator | Jul → Dec 2011 | — | University of Ottawa | Unknown | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00159146 Comparator | Aug 2002 → Sep 2007 | major depressive disorder | Hillerod Hospital, Denmark | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-12-13 | Actimed Therapeutics Ltd | Results Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle actimedtherapeutics.com ↗
Moreover, bioavailability of S-pindolol after equivalent doses of racemic pindolol and S-pindolol benzoate was comparable, and although not a prespecified objective, formal bioequivalence margins were met. |
| 2023-09-07 | Actimed Therapeutics Ltd | Regulatory Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia actimedtherapeutics.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pindolol | “Other names:
acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗15“Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “timolol, acebutolol, penbutolol pindolol, carvedilol” NCT00684489 ↗ “pindolol” NCT04767061 ↗ “pindolol” NCT04757584 ↗ |
| Known as | (+/-)-LB-46 | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | (rs)-pindolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Apo-pindol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Betadren | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Betapindol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Blocklin-l | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Calvisken | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Carvisken | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Decreten | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Dl-lb-46 | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Dl-pindolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Durapindol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Glauco-visken | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | NSC-757276 | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Pectobloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Pinbetol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Pindolol component of viskazide | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | pindolol/Viskene | “pindolol/Viskene” NCT01219686 ↗ |
| Known as | Prinodolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Pynastin | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Known as | Visken | ChEMBL registry synonym — accepted as the source's own label CHEMBL500 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor partial agonist” CHEMBL500 ↗1“Beta-1 adrenergic receptor partial agonist” CHEMBL500 ↗ |
| Action | Inhibit | “By its antagonist action on the serotonin 1A receptor pindolol is hypothesized to reduce the down-regulation mechanisms of antidepressants.” NCT01219686 ↗ |
| Modality | Small molecule | — CHEMBL500 ↗ |
| Route | Oral | “Pill orally administered.” NCT00931775 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor partial agonist” CHEMBL500 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor partial agonist” CHEMBL500 ↗ |